United States Diagnostics Market By Product Type (Reagents, Instruments, Software & Services), By Type of Test (Infectious Disease Testing, Lipid Panel, Metabolic Panel, Others), By Technique (Immunodiagnostics, Clinical Techniques, Molecular Diagnostics, Tissue Diagnostics, Others), By Usability (Reusable, Disposable), By Application (Infectious Diseases {Human Papillomavirus, Hepatitis, Tuberculosis, Hospital-Acquired Infections, COVID-19}, Cancer, Sexually Transmitted Diseases, Others), By End User (Hospitals, Public labs, Diagnostic Centers, Point-of-Care Testing Centers, Private or Commercial Laboratories, Others), By Region, Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 38.91 Billion
CAGR (2026-2031)	9.12%
Fastest Growing Segment	Infectious Disease Testing
Largest Market	Mid-West
Market Size (2031)	USD 65.69 Billion

Market Overview

The United States Diagnostics Market will grow from USD 38.91 Billion in 2025 to USD 65.69 Billion by 2031 at a 9.12% CAGR. The United States diagnostics market encompasses the development and deployment of various tests and procedures utilized by healthcare professionals to identify diseases, monitor conditions, and guide treatment decisions. Key drivers supporting this market's expansion include the increasing prevalence of chronic and infectious diseases, a growing geriatric population necessitating routine screenings, and the continuous demand for early and accurate disease detection.

However, market expansion faces a significant impediment from regulatory changes. For example, according to the Association for Diagnostics & Laboratory Medicine (ADLM), in September 2024, a survey indicated that 48% of clinical laboratories performing laboratory developed tests (LDTs) would discontinue these tests if the new Food and Drug Administration rule on LDT oversight becomes effective, impacting patient access to critical diagnostics. This potential reduction in test availability poses a considerable challenge to market accessibility and innovation.

Key Market Drivers

Disease Burden and Aging Demographics Driving Diagnostics Demand
The growing burden of chronic and infectious diseases represents a fundamental driver for the United States diagnostics market. This directly necessitates more diagnostic testing for early detection, monitoring, and treatment guidance, as healthcare systems strive to manage and mitigate the impact of widespread conditions. For example, according to the Centers for Disease Control and Prevention, in March 2026, during the 2024-2025 flu season, an estimated 51 million influenza-related illnesses occurred in the United States. The increasing prevalence of chronic conditions such as diabetes and cardiovascular disease also fuels demand for continuous diagnostic services. This escalating disease burden, coupled with the aging demographic, ensures a sustained and growing need for diagnostic tools and services across various healthcare settings.

Advancements in Diagnostics Technology Reshape the Market
Advancements in diagnostic technologies are significantly reshaping the United States diagnostics market by introducing more accurate, rapid, and less invasive testing methods. Innovations such as artificial intelligence-powered diagnostics and molecular testing are enhancing diagnostic capabilities, allowing for earlier and more precise disease identification. According to the FDA, in March 2026, over 1,300 AI-enabled medical devices had been authorized as of 2025-2026, with over 75% impacting imaging and diagnostics. These technological strides lead to improved patient outcomes and create new market segments. This sustained innovation, combined with overall rising healthcare expenditures, underpins the market's trajectory; according to the Centers for Medicare & Medicaid Services, in 2025, national health spending is projected to have reached $5.7 trillion.

Download Free Sample Report

Key Market Challenges

Regulatory Uncertainty Impedes Diagnostics Market Expansion
Regulatory changes represent a significant impediment to the expansion of the United States diagnostics market. While initial concerns focused on the potential impact of the Food and Drug Administration's rule on Laboratory Developed Test (LDT) oversight, which, if enacted, was projected to lead to the discontinuation of many tests, the broader regulatory environment continues to create instability. Such regulatory uncertainty hinders investment in new diagnostic platforms and slows the development cycle for innovative tests, impacting patient access to critical tools.

Medicare Payment Cuts Limit Laboratory Investment
Moreover, direct financial pressures from other regulatory policies also constrain market growth. For instance, according to the American Clinical Laboratory Association, in January 2026, without legislative intervention, approximately 800 laboratory tests were subject to Medicare payment cuts of up to 15% under the Clinical Laboratory Fee Schedule. These reductions in reimbursement directly impact the operational budgets of diagnostic laboratories, thereby limiting their capacity to invest in advanced technologies, expand testing menus, and maintain financial sustainability. This cumulative effect of regulatory burdens impedes market accessibility and the introduction of novel diagnostic solutions.

Key Market Trends

Shift to Decentralized Point-of-Care Diagnostics
The United States diagnostics market is significantly influenced by a palpable shift towards decentralized point-of-care diagnostics, which emphasizes bringing testing closer to the patient. This trend addresses the need for faster results and improved accessibility, particularly outside traditional laboratory settings, thereby streamlining patient management and reducing turnaround times for critical diagnostic information. These advancements empower clinicians to make immediate treatment decisions, minimizing delays that can impact patient outcomes. For instance, according to Co-Diagnostics, Inc., in July 2026, the company completed clinical studies for its Co-Dx™ PCR Flu A/B & RSV test, involving over 1,400 symptomatic patients across 9 US clinical sites, demonstrating significant real-world evaluation of decentralized testing. This expansion of easily deployable diagnostic platforms is reshaping how healthcare services are delivered across various settings, from primary care offices to remote clinics.

Growth of Precision and Personalized Medicine Diagnostics
Another crucial trend shaping the market is the accelerating growth in precision and personalized medicine diagnostics. This involves tailoring medical treatments and preventive strategies to an individual’s unique genetic makeup, environment, and lifestyle, moving beyond a one-size-fits-all approach. The integration of advanced diagnostics to identify specific biomarkers allows for targeted therapies that promise higher efficacy and fewer adverse effects. This necessitates sophisticated testing that informs specific therapeutic choices. According to Top Doctor Magazine, in March 2026, the compounding pharmacy sector, a key personalized medicine delivery mechanism, was projected to grow from $13.99 billion in 2025, underscoring the increasing demand for customized medical solutions driven by personalized diagnostics. The continuous development of companion diagnostics and genetic profiling tools is integral to this evolution, enhancing the ability to select optimal treatments for individual patients.

Segmental Insights

Infectious Disease Testing and Enabling Technologies Drive Growth in U.S. Diagnostics, with Regulatory Support.
The United States Diagnostics Market is experiencing significant expansion, with Infectious Disease Testing identified as a particularly fast-growing segment. This rapid growth is primarily driven by the increasing prevalence of various infectious diseases and the continuous demand for swift, accurate diagnostic solutions to enable early detection and effective management. Technological advancements, including innovations in molecular diagnostics and point-of-care testing, further enhance diagnostic capabilities and accessibility. Additionally, supportive regulatory frameworks from bodies such as the Food and Drug Administration (FDA) and initiatives from the Centers for Disease Control and Prevention (CDC) to improve disease surveillance and response contribute to market acceleration.

Regional Insights

Midwest Emerges as a Leader in U.S. Diagnostics
The Mid-West region holds a prominent position within the United States diagnostics market, primarily driven by its advanced healthcare infrastructure and considerable per capita healthcare expenditure. This regional leadership is further reinforced by the strong presence of leading diagnostic companies and significant diagnostic innovation originating from diverse medical institutions across the area. Recent strategic investments in expanding laboratory and diagnostic facilities throughout the Mid-West underscore the region’s sustained growth and commitment to broadening access to essential diagnostic services.

Recent Developments

• In December 2025, Roche obtained U.S. Food and Drug Administration (FDA) 510(k) clearance and a CLIA waiver for its first molecular point-of-care assay designed to identify Bordetella infections, including whooping cough. This new diagnostic test, performed on the cobas Liat system, delivers results in approximately 15 minutes. The launch of this assay significantly enhances Roche's point-of-care portfolio by enabling rapid on-site diagnosis in healthcare settings throughout the United States. This development provides clinicians with a crucial tool for swift detection and management of Bordetella infections in the U.S. diagnostics market.
• In July 2025, PHASE Scientific entered into an exclusive U.S. distribution agreement with Lumos Diagnostics for the FebriDx® rapid point-of-care test. This collaboration introduces a diagnostic tool to the United States that can differentiate between bacterial and non-bacterial acute respiratory infections using a single blood sample within approximately ten minutes. The agreement expands the availability of rapid diagnostics in the U.S. market, addressing the demand for quick and effective on-site testing for common respiratory illnesses. This initiative supports timely clinical decisions and improved patient care within the United States.
• In October 2024, Siemens Healthineers secured U.S. Food and Drug Administration (FDA) clearance for its Atellica IM High-Sensitivity Troponin I test. This diagnostic advancement allows for the prediction of major adverse cardiac events and all-cause mortality up to one year in patients presenting with symptoms suggestive of acute coronary syndrome. The test, which provides results rapidly, offers a critical new prognostic tool for healthcare providers in the United States. Its availability is expected to enhance early intervention strategies and improve patient triage in emergency departments across the U.S. diagnostics market.
• In June 2024, Abbott received U.S. Food and Drug Administration (FDA) approval for over-the-counter (OTC) versions of two new continuous glucose monitoring systems, Lingo and Libre Rio. These systems are based on existing Libre technology and aim to expand glucose management solutions for consumers in the United States. Lingo is designed for general wellness tracking, while Libre Rio caters to adults with Type 2 diabetes who do not rely on insulin therapy. This regulatory clearance significantly broadens accessibility to advanced diagnostic tools within the U.S. diagnostics market, enabling more individuals to monitor their glucose levels without a prescription.

Key Market Players

• Abbott Laboratories, Inc.
• Danaher Corporation
• Thermo Fisher Scientific, Inc.
• Johnson & Johnson
• Ortho-Clinical Diagnostics, Inc.
• Becton, Dickinson, and Company
• Bio-Rad Laboratories, Inc.
• Roche Diagnostics Corporation
• Siemens Medical Solutions USA, Inc.
• Biomerieux Inc.

By Product Type	By Type of Test	By Technique	By Usability	By Application	By End User	By Region
Reagents Instruments Software & Services	Infectious Disease Testing Lipid Panel Metabolic Panel Others	Immunodiagnostics Clinical Techniques Molecular Diagnostics Tissue Diagnostics Others	Reusable Disposable	Infectious Diseases {Human Papillomavirus Hepatitis Tuberculosis Hospital-Acquired Infections COVID-19} Cancer Sexually Transmitted Diseases Others	Hospitals Public labs Diagnostic Centers Point-of-Care Testing Centers Private or Commercial Laboratories Others	Northeast Midwest South West

Report Scope:

In this report, the United States Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Diagnostics Market, By Product Type:

• Reagents
• Instruments
• Software & Services

• United States Diagnostics Market, By Type of Test:

• Infectious Disease Testing
• Lipid Panel
• Metabolic Panel
• Others

• United States Diagnostics Market, By Technique:

• Immunodiagnostics
• Clinical Techniques
• Molecular Diagnostics
• Tissue Diagnostics
• Others

• United States Diagnostics Market, By Usability:

• Reusable
• Disposable

• United States Diagnostics Market, By Application:

• Infectious Diseases {Human Papillomavirus
• Hepatitis
• Tuberculosis
• Hospital-Acquired Infections
• COVID-19}
• Cancer
• Sexually Transmitted Diseases
• Others

• United States Diagnostics Market, By End User:

• Hospitals
• Public labs
• Diagnostic Centers
• Point-of-Care Testing Centers
• Private or Commercial Laboratories
• Others

• United States Diagnostics Market, By Region:

• Northeast
• Midwest
• South
• West